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Abstract
Diagnostic tests play an important role in the clinical decision-making process by providing information that enables patients 
to be identified and stratified to the most appropriate treatment and management strategies. Decision analytic modelling 
facilitates the synthesis of evidence from multiple sources to evaluate the cost effectiveness of diagnostic tests. This study 
critically reviews the methods used to model the cost effectiveness of diagnostic tests in UK National Institute for Health 
Research (NIHR) Health Technology Assessment (HTA) reports. UK NIHR HTA reports published between 2009 and 2018 
were screened to identify those reporting an economic evaluation of a diagnostic test using decision analytic modelling. Exist-
ing decision modelling checklists were identified in the literature and a modified checklist tailored to diagnostic economic 
evaluations was developed, piloted and used to assess the diagnostic models in HTA reports. Of 728 HTA reports published 
during the study period, 55 met the inclusion criteria. The majority of models performed well with a clearly defined decision 
problem and analytical perspective (89% of HTAs met the criterion). The model structure usually reflected the care pathway 
and progression of the health condition. However, there are areas requiring improvement. These are predominantly system-
atic identification of treatment effects (20% met), poor selection of comparators (50% met) and assumed independence of 
tests used in sequence (32% took correlation between sequential tests into consideration). The complexity and constraints 
of performing decision analysis of diagnostic tests on costs and health outcomes makes it particularly challenging and, as 
a result, quality issues remain. This review provides a comprehensive assessment of modelling in HTA reports, highlights 
problems and gives recommendations for future diagnostic modelling practice.
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Key Points for Decision Makers 
A diagnostic test-specific checklist to assess decision 
modelling has been developed and piloted.
The models in Health Technology Assessments tended to 
be of relative high quality but also suffered key problems 
including lacking justification of comparators, lacking 
model validation, insufficient efforts to examine struc-
tural uncertainty and obtain treatment effects data as well 
as assuming independence of tests in sequence.
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1 Introduction
Diagnostic tests play an important role in the clinical deci-
sion-making process by providing information that enables 
patients to be identified and stratified to the most appropriate 
treatment and management strategies. The value of diag-
nostic tests and its implication for technology assessment 
has long been recognised and discussed [1, 2]. Historically, 
the primary focus of test evaluation research has been the 
estimation of clinical accuracy. However, a recent system-
atic review of test–treatment randomised controlled trials 
(RCTs) demonstrates that improvements in test accuracy are 
rarely an indicator of patient health benefit [3]. Therefore, 
to evaluate the impact of a new diagnostic test on patient 
health outcomes, it must be examined as part of a broader 
test–treatment management strategy.
Test–treatment RCTs are uncommon due to the many 
challenges in conducting such trials and, of those that have 
been carried out, many have failed to deliver robust results 
[4]. Decision analytic modelling is now recognised as a prac-
tical alternative [4, 5]. It facilitates the evaluation of both the 
economic (i.e. cost) and clinical (i.e. health benefit) impacts 
of introducing a new test simultaneously. It also overcomes 
a number of additional methodological hurdles common to 
diagnostic test evaluation: the need to link evidence from a 
number of different sources, the lack of long-term outcome 
data in scenarios where only intermediate endpoints (e.g. 
test accuracy) have been measured or where only short-term 
follow up is possible and the need to compare many inter-
ventions (e.g. testing strategies/pathways), which may not 
be feasible/practical within a single RCT [6].
There is currently limited understanding of how deci-
sion analytical modelling has been used in economic 
evaluations of diagnostic tests. Existing reviews have 
appraised economic evaluations of diagnostic tests more 
generally but have not focused specifically on the mod-
elling. Further, much of the literature assessing the eco-
nomic evaluation of diagnostic tests is now outdated. In 
1999, Severens and van der Wilt published a review of 
economic evaluations of diagnostic tests and found that 
many failed to adhere to guidelines for economic evalua-
tion [7]. A further review of cost-utility studies of diag-
nostic tests in 2011 found that many models excluded key 
parameters such as test safety or the potential harms from 
testing [8].
Other more recent work has focused on how diagnos-
tic evidence has been incorporated into economic models 
[9–11]. Doble et al. reviewed models of companion diag-
nostics for targeted oncology therapies, reporting that out 
of a total of 30 included studies, 12 studies incorporated 
test accuracy parameters in the model whereas the remain-
ing 18 studies only included the cost of testing [12]. A 
final study reviewed the use of evidence in decision mod-
els based on published UK National Institute of Health 
Research (NIHR) Health Technology Assessment (HTA) 
reports [13]. This study briefly assessed the models used 
but covered all HTAs rather than focusing on diagnostics. 
This work has recently been further developed into a pro-
posed analytical framework for diagnostic and prognostic 
test assessments for HTAs [14].
In the UK, the National Institute for Health and Care 
Excellence (NICE) Diagnostic Assessment Programme 
was only established in 2010. The economic evaluation 
of diagnostic tests and the appropriate methods for such 
analyses is a relatively new area of research under active 
development. Specifically, model-based economic evalu-
ations of diagnostics require careful consideration: model 
structure must accurately reflect the clinical care pathway, 
key decision points and disease progression. Parameter 
selection should reflect the best evidence available, and 
all analytical uncertainties must be fully explored. The 
challenges in this field have recently been highlighted by a 
Medical Research Centre call for methodology research to 
support the assessment of diagnostic technologies and the 
development of diagnostic service guidelines for health-
care decision making such as by NICE [15]. This review 
provides an update on the assessment of model-based eco-
nomic evaluations of diagnostics tests, which is urgently 
needed to inform and contribute to methodological and 
policy developments such as the NICE diagnostic assess-
ment process in this area.
2  Methods
There were four key steps in this review: (i) identification of 
relevant UK NIHR HTA reports, (ii) development and pilot-
ing of a reporting checklist to assess model-based economic 
evaluations of diagnostic tests, (iii) data extraction and (iv) 
data analysis.
2.1  Identifying Diagnostic UK National Institute 
of Health Research (NIHR) Health Technology 
Assessments (HTAs) to be Included 
in the Review
The titles and abstracts of all UK NIHR HTA reports pub-
lished between May 2009 and July 2018 were independently 
screened by two authors (TF and BS), with disagreements 
resolved by discussion with LA and YY as required, to iden-
tify model-based economic evaluations of diagnostic tests. 
Reports were excluded if the primary role of the test(s) was 
not diagnosis (e.g. screening, treatment selection, prognosis 
or monitoring). The methods used to synthesise test accuracy 
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data and the extent that these results informed health eco-
nomic model parameters have been examined in a parallel 
study [16].
2.2  Developing and Piloting of a Reporting 
Checklist to Assess Model‑Based Economic 
Evaluations of Diagnostic Tests
A rapid search of the literature was conducted to identify 
existing checklists or guidelines intended for the develop-
ment or reporting of decision models in health care. Three 
checklists were identified: Philips et al. [17], Ramos et al. 
[18] and the Consolidated Health Economic Evaluation 
Reporting Standards (CHEERS) statement [19]. Several 
reports related to good research practices for modelling 
produced jointly by the International Society for Pharma-
coeconomics and Outcomes Research (ISPOR) and the 
Society for Medical Decision Making (SMDM) were also 
identified [20–25].
A reporting checklist to assess model-based economic 
evaluations of diagnostic tests was developed based on 
these checklists and guidelines, primarily derived from 
the Philips et al. checklist [17]. The checklist was piloted 
(by LA) on five HTA reports and then modified to include 
key items related to diagnostic tests. Two reviewers (LA 
and YY) then independently reviewed and extracted data 
for a sub-group of 24 HTA reports using the refined 
checklist and the results were compared. Any differences 
and disagreements were identified and discussed between 
LA, YY and JB. This resulted in further refinement of the 
questions and the associated scoring system to maximise 
consistency.
The final checklist is presented in Table 1. It contains 
39 questions and covers 11 key domains of good modelling 
practice. For each question, HTA reports were classified as 
having ‘not met’ (scored as 0), ‘partially met’ (scored as 
0.5), or ‘met’ (scored as 1) the stated criterion. ‘Partially 
met’ was used to reflect situations in which reports implied 
that some work had been done to meet the criteria. For 
example, for the question ‘Have diagnostic accuracy data 
been derived from high quality data sources’, the report 
might indicate that this had been done for most diagnostic 
accuracy parameters but not all. Judgements were com-
monly made on the basis of self-reported evidence or 
efforts from the authors of the HTA reports rather than con-
ducting independent appraisals. Not applicable (‘n/a’) was 
also possible for some questions. For example, if a decision 
tree model was developed, the question ‘Does the cycle 
reflect the progression and transition of health states?’ 
would not be applicable, since that is a Markov-specific 
model characteristic. Detailed information on how the 
responses were defined can be found in Appendix 1 (see 
Electronic Supplementary Material).
2.3  Data Extraction
Background information (e.g. year of publication, condition 
of interest, test type and population of interest) was extracted 
from each UK NIHR HTA report. Test type was categorised 
as (i) imaging, (ii) genetic, (iii) laboratory, (iv) point of care. 
These categories were not necessarily mutually exclusive; 
for example, a genetic test could also be a laboratory test. 
Tests that did not fall into one of these categories were clas-
sified as ‘other’.
The four following additional details were also extracted 
from each report: (i) details of the model structure, (ii) 
whether any formal assessment tools were used to evaluate 
the quality of studies providing data to inform model param-
eters, (iii) which outcome measures were reported and (iv) 
the perspective adopted for the analysis.
The checklist was then completed for each report by a 
single reviewer (LA). The checklist was independently 
completed by a second reviewer (YY) for eight randomly 
selected HTAs. Agreement between the two reviewers was 
examined. Agreement was defined as absolute agreement 
where both reviewers gave the same responses to a question. 
A partial agreement was where one reviewer gave ‘met’ but 
the other gave ‘partially met’, or where ‘partially met’ and 
‘not met’ were given. The proportions of absolute and partial 
agreements between reviewers for individual questions and 
domains are reported.
All extracted data was stored and analysed in Microsoft 
Excel.
2.4  Data Analysis
The characteristics of the HTA reports were summarised 
and the proportion of responses to the eleven assessment 
domains across all included HTAs was calculated. For 
example, the first domain ‘Decision problem and scope 
specified’ contains five questions. Therefore, the denomi-
nator (the total possible responses) is N*5 where N is the 
number of included HTAs. Then the sum of responses 
being ‘not met, ‘partially met’ and ‘met’ for the five ques-
tions among the N HTAs were calculated as the numerator, 
and the proportion of each response was calculated.
Responses were broken down by checklist domain, test 
type and year. Responses to individual questions were also 
reviewed to identify areas of particular weakness.
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Table 1  Checklist for model-based economic evaluations of diagnostic tests
Domain Question
1. Decision problem and scope specified 1. Is there a clear statement of the decision problem?
2 Is the perspective of the model stated clearly?
3 Has the target population been identified?
4 Are the model inputs consistent with the stated perspective?
5 Are the primary outcomes of the model consistent with the perspective, scope and overall 
objective of the model?
2. Identification and description of comparators 6. Have all feasible and practical options been identified?
7. Have the comparators being evaluated been clearly described?
8. If comparators have been excluded from the evaluation, have these exclusions been justi-
fied?
3. Appropriate data identification 9. Are the data identification methods transparent, systematic and appropriate given the 
objectives of the model?
4. Sufficient detail for data incorporation 10. Have all data incorporated into the model been described and referenced in sufficient 
detail?
11. Where choices have been made between data sources, are these justified appropriately?
12. Are transition probabilities calculated appropriately?
13. Has discounting been conducted?
5. Quality and incorporation of test accuracy data 14. Has the quality of the test accuracy data been assessed?
15. Have diagnostic accuracy data been derived from high quality data sources (hierarchy of 
evidence)?
16. Are tests in sequence treated dependently, where appropriate?
6. Quality and incorporation of treatment data 17. Has the quality of the treatment effect data been assessed?
18. Have relative treatment effects been derived from high quality data sources (hierarchy of 
evidence)?
7. Source and incorporation of cost data 19. Has the source of cost data been presented clearly?
20. Have costs been inflated to a specific year, where appropriate?
8. Source and incorporation of utility data 21. Is the source for the utility weights referenced and justified?
22. Are the utilities incorporated into the model appropriately?
9. Model structure 23. Have the reasons behind the type of decision analytic model chosen been fully described 
and justified?
24. Has a systematic review of existing economic evaluations been carried out?
25. Is the structure of the model consistent with a coherent theory of the health condition 
under evaluation?
26. Are the structural assumptions underpinning the model transparent and justified?
27. Have the methods used to extrapolate short-term results to final outcomes been docu-
mented and justified?
28. Has the time horizon been stated and justified?
29. Has cycle length of Markov models been justified?
10. Uncertainty 30. Has parameter uncertainty been addressed via sensitivity analysis?
31. Has probabilistic sensitivity analysis been carried out? If not, has this omission been 
justified?
32. If data are incorporated as point estimates, are the ranges used for sensitivity analysis 
stated clearly and justified?
33. If data have been incorporated as distributions, has the choice of distribution for each 
parameter been described and justified?
34. Have structural uncertainties been addressed via sensitivity analysis?
35. Have alternative assumptions related to final outcomes been explored through sensitivity 
analysis?
36. Has value of information analysis been done?
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3  Results
3.1  Search Results
The search results and the screening-for-inclusion process 
are reported in Fig. 1.
3.2  General Description of the Conditions, Tests 
and Models in the Included HTAs
Characteristics of the 55 included HTAs reviewed can be 
found in Table 2. The health conditions to be diagnosed 
included various chronic diseases (44%, n = 24/55), can-
cer (27%, n = 15/55), acute conditions (16%, n = 9/55) and 
Table 1  (continued)
Domain Question
11. Validity 37. Has the face validity been reviewed by someone external to the model developers?
38. Has the mathematical logic of the model been assessed? (e.g. using null and extreme 
values)
39. Have the model and its results been compared to the findings of other models and studies, 
and any disagreements or inconsistencies been explained (cross-validity)?
Fig. 1  Search results. HTAs 
Health Technology Assessments 728 HTAs Published from 
May 2009 to July 2018
Exclusion: 565 
Treatment/intervention/methodology 
163 (22%) Evaluate at least 
one test 
Exclusion: 80
Screening (23)
Monitoring (28)
Disease progress/prognosis (16)
Treatment selection (13) 
Exclusion: 28No health economic 
decision modelling
83 (11%) Economic evaluation of 
test for diagnosis 
55 (8%) included in the final 
review   
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infections (13%, n = 7/55). Four types of diagnostic test were 
identified in the reviewed HTAs: (i) imaging, (ii) genetic, 
(iii) laboratory, (iv) point of care. Imaging technologies 
were the most commonly evaluated tests (40%, n = 22/55). 
Of those that did not fall into one of the defined test types, 
two were clinical decision rules (i.e. where a combination 
of signs, symptoms and test results determine a patient’s 
diagnosis according to a specified algorithm). In four of 
the models, the test under evaluation was not compared 
with a reference standard [26–29]. The remaining models 
either compared the results of the test under evaluation with 
another test (55%, n = 30/55) or to clinical criteria/follow-up 
(38%, n = 21/55).
Decision trees were the most commonly applied model 
structure (69%, n = 38/55), either alone (42%, n = 23/55) 
or in combination with a Markov model (27%, n = 15/55). 
This approach stratifies a simulated patient cohort into dif-
ferent groups based on the result of the test, using disease 
prevalence and test accuracy to determine the proportions 
of individuals in each group. Markov modelling was imple-
mented in around a third of the HTAs (36%, n = 20/55). This 
method is used to capture longer-term effects (e.g. life-time 
disease progression).
The vast majority of models (95%, n = 52/55) measured 
outcomes using quality-adjusted life-years. The number 
of cases detected or avoided were reported in the remain-
ing three models [26, 30, 31],. All analyses adopted the 
perspective of the NHS or NHS and social care, which 
is recommended for this type of evaluation by NICE in 
the UK [32]. Sixteen HTAs included in the review were 
Table 2  Summary description for the HTAs included in the review
*May not add up to 100% due to rounding
Categories Number of studies in each 
category [n (%)]*(N = 55)
Condition to be diagnosed Cancer 15 (27)
Chronic diseases 24 (44)
Infections 7 (13)
Acute conditions 9 (16)
Type of Test Evaluated Genetic 7 (13)
Imaging 22 (40)
Lab-based 15 (27)
Point of Care 6 (11)
Others 5 (9)
Year of Publication 2009 5 (9)
2010 2 (4)
2011 5 (9)
2012 3 (5)
2013 11 (20)
2014 6 (11)
2015 8 (15)
2016 7 (13)
2017 5 (10)
2018 (till July) 3 (5)
Was a reference standard reported? Yes, another test 30 (55)
Yes, clinical criteria or clinical follow up 21 (38)
No 4 (7)
What type of modelling was implemented? Decision tree only 23 (42)
Markov model only 5 (9)
Decision tree and Markov 15 (27)
Individual patient simulation model 7 (13)
Discrete event simulation and dynamic transmission model 1 (2)
Decision tree and individual patient simulation model 1 (2)
Decision tree and discrete event simulation model 3 (5)
What outcome measures were reported? QALY 52 (95)
Case detected or avoided 3 (5)
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Diagnostic Assessment Reports (DAR) and provided 
an evidence base for use to support development NICE 
diagnostic guidance [33]. Which HTA is linked to which 
specific NICE diagnostic guidance can be found in online 
supplementary material containing full data extraction at 
https ://figsh are.com/s/643c9 a69d9 56780 eb0a8 .
3.3  Assessment of Model‑Based Evaluations 
of Diagnostic Tests
The degree of agreement between data extracted from the 
random sample of eight HTAs using the modified check-
list by the two reviewers is reported in Table 3. Agreement 
depended on the quality domains concerned and whether 
absolute or partial agreement was measured. Among the 
11 assessment domains, two achieved ≥ 80% absolute 
agreement, another six achieved > 60% absolute agreement 
and the remaining three domains achieved around 50% abso-
lute agreement. Six domains achieved > 80% partial agree-
ment, four domains achieved > 60% and only one domain 
achieved around 50% partial agreement.
The results from the assessment of the decision analytic 
models are summarised in Fig. 2. Specification of the deci-
sion problem and scope was generally clearly reported (89% 
of reports met the criteria, 11% partially met). Evaluation 
of the validity of the models was generally poor, with over 
half failing to meet or even partially meet the criteria. It 
should be noted that reviewer agreement for this domain was 
low, which could highlight some general uncertainty in what 
would be required and reported to evaluate the validity of a 
model. The quality of the treatment data incorporated into 
Table 3  Percentage of absolute 
and partial agreement of data 
extracted by two reviewers
* ≤ 60%), ** 60–80%, *** ≥ over 80%
Quality domain Absolute agreement (%) Partial 
agreement 
(%)
1. Decision problem and scope specified 90*** 95***
2. Identification and description of comparators 46* 67**
3. Appropriate data identification 63** 81***
4. Sufficient detail for data incorporation 69** 81***
5. Quality and incorporation of test accuracy data 54* 81***
6. Quality and incorporation of treatment data 63** 75**
7. Source and incorporation of cost data 63** 84***
8. Source and incorporation of utility data 81*** 69**
9. Model Structure 66** 79**
10. Uncertainty 77** 88***
11. Validity 46* 54*
Fig. 2  Overall performance of 
models in the 55 included HTAs 
(2009–2018). HTAs Health 
Technology Assessments
89%
59% 58%
65%
50%
35%
61%
78%
72%
49%
31%
11%
25%
38%
13%
19%
30%
17%
7%
14%
21%
17%
5%
4%
5%
13%
29%
16% 5%
4%
28%
52%
10%
17% 17%
5% 5% 9% 10%
2% 1%
0%
20%
40%
60%
80%
100%
n/a
Not met
Partially met
Met
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the models was also of particular concern, with only 35% of 
reports meeting the required criteria.
For the remaining domains, the proportion of responses 
that fully met the criteria ranged from 49 to 78%. Most of the 
remaining reports partially met the criteria, although there 
were a few domains where a notable proportion failed to 
either meet or partially meet the criteria (uncertainty 28%, 
source and incorporation of cost data 16%, quality and incor-
poration of test accuracy 13%).
A breakdown of the assessment results by type of diag-
nostic test and publication date is reported in Appendix 2 
(see Electronic Supplementary Material). In general, the 
assessment results were similar across the different types 
of tests. Across the seven year groups analysed (2009/10, 
2011/12, 2013, 2014, 2015, 2016, 2017/18), there is no obvi-
ous trend observed in modelling assessment and there are 
variations across assessment domains.
3.4  Issues of Particular Concern in the Assessment
In Table 4, on the basis of reviewing the performance of 
domains and questions within each domain, we report the 
results for those questions that scored poorly and which are 
regarded as of particular importance (full data extraction 
results can be found as online supplementary material in 
https ://figsh are.com/s/643c9 a69d9 56780 eb0a8 ).
Where comparators were excluded from their model, 
only half of HTAs clearly justified reasons for exclusion. 
The quality of treatment effect data included in the mod-
els was not systematically evaluated; only 20% fully met 
this criterion and just over half (51%) failed to meet it at 
all. When the issue is relevant, most HTAs (68%) assumed 
independence between the tests; that is, the result of one test 
does not alter the diagnostic accuracy of the second so the 
combined sensitivity and specificity of sequential tests were 
obtained by simply multiplying the probabilities of each. 
Only just over half (53%) of HTAs reported clearly how 
transition probabilities were calculated. Only 26% clearly 
described and justified the choice of distributions used for 
each parameter and 64% partially did this. Sensitivity analy-
ses to explore uncertainty in the model structure were rarely 
reported with none of the HTAs fully meeting this criterion, 
78% not meeting and 22% partially meeting. Similarly, face 
validity and cross-validity were rarely properly done.
4  Discussion
This study assesses model-based economic evaluations of 
diagnostic tests featuring in UK NIHR HTAs published 
between 2009 and 2018. To achieve this, we developed an 
assessment checklist tailored specifically to account for the 
nuances of evaluating diagnostic tests using decision ana-
lytic modelling. Most items included in the checklist are 
applicable to critical appraisal of decision models in general, 
but some items capture specific key aspects of modelling 
diagnostics, such as the linkage between test accuracy data 
to patient management decisions and the efficacy of any 
treatments given.
In general, the reviewed models scored moderately well 
on the assessment, with around half of the included HTAs 
fully or partially meeting most of the criteria. All analyses 
adopted the perspective of the NHS or NHS and social care, 
which is recommended for this type of evaluation by NICE 
in the UK [32]. Our assessment did, however, highlight some 
areas for possible improvement.
1. Poor reporting and/or justification of comparators
  In economic evaluations, it is important to include all 
possible comparators or clearly justify their exclusion 
because the evaluation is, by nature, a comparison in 
which the selection of comparators may change the con-
Table 4  Checklist questions with poor performances n (%)
The percentages might not add up to 100% due to rounding. Percentages were calculated by n/N (i.e. n/a are excluded)
Questions Met Partially met Not met N 
(Exclud-
ing n/a)
If comparators have been excluded from the evaluation, have these exclusions been justified? 19 (50) 15 (39) 4 (11) 38
Has the quality of the treatment effect data been assessed? 10 (20) 15 (29) 26 (51) 51
Are transition probabilities calculated appropriately? 19 (66) 6 (21) 4 (14) 29
Are tests in sequence treated dependently, where appropriate? 11 (32) 8 (24) 15 (44) 34
If data have been incorporated as distributions, has the choice of distribution for each param-
eter been described and justified?
12 (26) 30 (64) 5 (11) 47
Have structural uncertainties been addressed via sensitivity analysis? 0 (0) 12 (22) 43 (78) 55
Has the face validity been reviewed by someone external to the model developers? 16 (29) 15 (27) 24 (44) 55
Have the model and its results been compared to the findings of other models and studies, and 
any disagreements or inconsistencies been explained (cross-validity)?
27 (50) 8 (15) 19 (35) 54
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clusions of the analysis. We found that reporting of this 
aspect was poor and the selection of comparators was 
rarely justified. Where authors did justify the exclusion 
of comparators, the reasons given were very vague (e.g. 
‘not applicable to the NHS’, ‘lack of evidence’, ‘beyond 
the scope’), making it impossible to judge whether these 
justifications were valid. Authors are recommended to 
provide justification for their choice of comparators, ide-
ally including a horizon scan of the diagnostic landscape 
with clinical experts’ opinions.
2. Poor reporting of transition probability calculations
  Transition probabilities are key model parameters. In 
decision tree models of diagnostic pathways, the preva-
lence of the target condition and the accuracy of the test 
are often used to inform transition probabilities. How-
ever, in Markov models, calculation of transition prob-
abilities between health states is typically more complex, 
in many cases relying on survival or clinical event data. 
In this context, the reporting of transition probability 
calculations was poor, making it difficult to judge the 
validity of these parameters. This also prevents other 
researchers from rebuilding the model in future evalua-
tions.
3. Treatment effect data—identification, quality assessment 
and synthesis (or lack of)
  Treatments are an important component of the test–
treatment pathway, linking the effects of diagnostics to 
patient health outcomes. However, in this review, we 
noted a stark difference in the rigour in which treat-
ment effect data was identified, quality assessed and 
synthesised compared with diagnostic accuracy data. 
Treatment effect data was rarely identified via system-
atic review and the quality of the evidence was rarely 
assessed. Furthermore, there was typically insufficient 
evidence identified to facilitate meta-analysis.
4. Lack of validation
  The face validity and cross-validity of the models 
reviewed were rarely assessed. The lack of cross-vali-
dation may be due to a lack of other published models 
to compare against but, if this is the case, then it needs 
to be clearly reported. Examination of the face validity 
of the model is crucial, particularly in this context where 
the evidence underpinning the model is likely to come 
from a wide range of sources (e.g. test accuracy stud-
ies, treatment effect studies, epidemiology studies) and 
therefore the linkage of this data could easily produce 
clinically spurious results. Presenting the model and its 
output to a team of relevant clinicians and experts in the 
field is vital to ensuring it reflects real-world clinical 
practice as far as possible.
5. Assuming independence of tests in sequence
  Diagnostic tests are often used sequentially in clinical 
practice and it is important to acknowledge and account 
for dependencies when this occurs. If a test is introduced 
as a means of identifying an appropriate group of indi-
viduals (i.e. a triage test) for a confirmatory test, this 
will directly impact on the prevalence and spectrum of 
disease among those referred for the confirmatory test. 
If the two tests measure a similar physiological concept 
(e.g. inflammation), then it is likely that there will be 
a correlation in the misdiagnoses that each test makes. 
This issue was largely ignored in the reviewed HTAs; 
the majority (68%) assumed the test results were inde-
pendent, potentially leading to biased outcomes. This 
issue could be accounted for by using either diagnostic 
accuracy studies from the tests used in sequence [34] or 
by attempting to model the correlation between tests in 
the sensitivity analysis [35, 36].
6. Structural uncertainty
  Although sensitivity analysis (including probabilis-
tic sensitivity analysis) was undertaken routinely, struc-
tural uncertainties were rarely examined in the reviewed 
HTAs. This is particularly pertinent to the evaluation of 
a novel diagnostic, as its position in and impact on the 
real-world care pathway and clinical practice (and hence 
the model structure) has not yet been demonstrated or 
confirmed. Model structure should ensure some flex-
ibility to allow exploring of various scenarios within 
sensitivities to reflect both the ‘ideal’ scenario and the 
‘messier’ reality of clinical practice.
4.1  Limitations of the Study
This review focused only on HTAs published between 2009 
and 2018 in the UK, and these publications represent just a 
subset of all model-based economic evaluations of diagnos-
tic tests. HTAs tend to allow more space for reporting than 
normal journal articles, undergo an extensive peer review 
process and are generally deemed of good quality. The areas 
for improvement outlined above are in most cases due to the 
inherent difficulties in performing model-based economic 
evaluations of diagnostic tests, rather than a reflection of the 
quality of the HTA reports themselves. Therefore, we believe 
that the issues that have been identified in this paper are 
likely to exist in similar studies and may be more prevalent.
Tests play different roles in patient care and the focus 
of this review was purely on diagnostic tests. We chose 
to exclude tests used for other purposes as the evidence 
requirements and data linkage for these models is likely 
to differ. Reviewing the model-based evaluations of tests 
used for other purposes (e.g. screening, prognosis, moni-
toring or treatment selection) would be an interesting addi-
tion to this work.
The checklist was developed to assess diagnostic mod-
els reported in HTAs. Although the checklist may not 
be able to provide a comprehensive quality appraisal of 
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models used in HTAs, it gives some indication of whether 
or to what extent important principles of analysis have 
been met or missed. Our checklist focuses on analytical 
principles and data identification, which supplements the 
recently published AGREEDT (an acronym of “AliGnment 
in the Reporting of Economic Evaluations of Diagnostic 
Tests and biomarkers AliGnment in the Reporting of Eco-
nomic Evaluations of Diagnostic Tests and biomarkers’) 
checklist with a focus on report and consideration during 
the early stages of modelling diagnostic tests [37]. During 
the development, the checklist was revised based on pilot-
ing in a subgroup of 24 HTAs. The checklist was also par-
tially validated by comparing agreements of data extrac-
tion between the two reviewers for a random sample of 
eight HTAs. Subjective judgements are inevitably involved 
in this type of assessment study and therefore absolute 
agreements between reviewers are sometimes difficult to 
achieve, as shown in the current study. This suggests that 
further validation is needed for the checklist, but our work 
provides the basis for the development of a fully validated 
diagnostic-relevant checklist, which is much needed.
5  Conclusions
Given the challenges in conducting clinical studies that 
fully capture the impact of diagnostic testing on patient 
outcomes, decision analytic modelling plays a critical role 
in diagnostic test evaluation. In this study, we have com-
prehensively assessed model-based economic evaluations 
of diagnostic tests within recent UK HTA reports. Our 
review recognised the complexity and difficulty in model-
ling the cost effectiveness of diagnostic tests.
It also highlights that tools and guidelines are needed 
to evaluate and promote improved model development, the 
systematic review of identification of evidence and valida-
tion for the evaluation of diagnostics in the future. We call 
for methods to efficiently examine structural uncertainty 
in modelling. We suggest methodological development to 
address the low-quality evidence or lack of evidence on 
diagnostic test accuracy, especially to quantify the impact 
of potential interdependency of multiple test combinations 
in parallel or sequentially within the diagnostic pathway.
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